MediciNova, Inc. (MNOV)

$2.27

-0.01 (-0.44%)
Rating:
Recommendation:
Buy
Symbol MNOV
Price $2.27
Beta 0.977
Volume Avg. 0.03M
Market Cap 111.335M
Shares () -
52 Week Range 2.08-4.65
1y Target Est -
DCF Unlevered MNOV DCF ->
DCF Levered MNOV LDCF ->
ROE -15.99% Sell
ROA -16.10% Sell
Operating Margin -
Debt / Equity 6.04% Neutral
P/E -
P/B 1.45 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest MNOV news


Dr. Yuichi Iwaki
Healthcare
Biotechnology
NASDAQ Global Market

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.